Aadi Bioscience, Inc. (AADI)
NASDAQ: AADI · IEX Real-Time Price · USD
1.430
-0.100 (-6.54%)
At close: Jul 19, 2024, 4:00 PM
1.510
+0.080 (5.59%)
Pre-market: Jul 22, 2024, 8:37 AM EDT
Aadi Bioscience Employees
Aadi Bioscience had 89 employees as of December 31, 2023. The number of employees increased by 10 or 12.66% compared to the previous year.
Employees
89
Change (1Y)
10
Growth (1Y)
12.66%
Revenue / Employee
$267,865
Profits / Employee
-$773,382
Market Cap
35.11M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 89 | 10 | 12.66% |
Dec 31, 2022 | 79 | 40 | 102.56% |
Dec 31, 2021 | 39 | 31 | 387.50% |
Dec 31, 2020 | 8 | - | - |
Related Stocks
Company Name | Employees |
---|---|
DarioHealth | 294 |
Achilles Therapeutics | 215 |
Precision Optics Corporation | 85 |
IceCure Medical | 77 |
Xilio Therapeutics | 73 |
iCAD, Inc. | 69 |
IGC Pharma | 67 |
IN8bio | 31 |
AADI News
- 7 weeks ago - Aadi Bioscience to Participate in the Jefferies Healthcare Conference - PRNewsWire
- 2 months ago - Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting - PRNewsWire
- 2 months ago - Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update - PRNewsWire
- 2 months ago - Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update - PRNewsWire
- 3 months ago - Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting - PRNewsWire
- 4 months ago - Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) - PRNewsWire
- 4 months ago - Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update - PRNewsWire
- 4 months ago - Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update - PRNewsWire